Experience with Dupilumab in Patient with Nephrotic Syndrome Receiving Rituximab Maintenance Therapy

Key Points

• To assess the effects of dupilumab in a nephrotic syndrome patient undergoing rituximab maintenance therapy.
• Patient case report of a 22-year-old male with nephrotic syndrome and atopic dermatitis.
• Initiation of dupilumab therapy after failure of topical treatments and cyclosporine.
• Monitoring of eczema severity and serum biomarkers over 10 months.
• Significant improvement in atopic dermatitis with IGA score reduced to 1 and EASI score to 1.5 after 10 months of treatment.
• Serum IgE levels decreased to 70 IU/mL and TARC levels to 74 pg/mL.
• No serious adverse events were reported, and nephrotic syndrome remained in remission for 3 years and 6 months.